Novel hepato‐preferential basal insulin peglispro ( <scp>BIL</scp> ) does not differentially affect insulin sensitivity compared with insulin glargine in patients with type 1 and type 2 diabetes

The need to reduce prandial insulin observed with BIL during phase 3 trials cannot be explained by the differential effects of BIL and GL on sensitivity to prandial insulin in either T1DM or T2DM.